Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 6
1952 13
1953 16
1954 16
1955 22
1956 33
1957 32
1958 39
1959 18
1960 24
1961 38
1962 34
1964 2
1965 7
1966 27
1967 48
1968 44
1969 34
1970 33
1971 33
1972 40
1973 43
1974 41
1975 37
1976 33
1977 39
1978 32
1979 26
1980 33
1981 26
1982 45
1983 29
1984 40
1985 44
1986 38
1987 26
1988 29
1989 53
1990 39
1991 53
1992 46
1993 58
1994 43
1995 56
1996 58
1997 49
1998 73
1999 53
2000 42
2001 54
2002 68
2003 105
2004 89
2005 90
2006 138
2007 147
2008 122
2009 146
2010 143
2011 149
2012 195
2013 204
2014 210
2015 202
2016 193
2017 203
2018 177
2019 92
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

4,112 results
Results by year
Filters applied: . Clear all
Page 1
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Perrot A, et al. Blood 2018 - Clinical Trial. PMID 30249784 Free PMC article.
The introduction of novel agents has led to major improvements in clinical outcomes for patients with multiple myeloma. To shorten evaluation times for new treatments, health agencies are currently examining minimal residual disease (MRD) as a surrogate end point in clinical trials. ...Our findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials....
The introduction of novel agents has led to major improvements in clinical outcomes for patients with multiple myeloma. To sho …
Metabolic Features of Multiple Myeloma.
El Arfani C, et al. Int J Mol Sci 2018 - Review. PMID 29662010 Free PMC article.
As part of these changes, metabolic rearrangements are identified in several cancers, including multiple myeloma (MM), which is a condition whereby malignant plasma cells accumulate in the bone marrow (BM). ...Therefore, this review will focus on changes in glucose and glutamine metabolism linked with the emergence of drug resistance. ...
As part of these changes, metabolic rearrangements are identified in several cancers, including multiple myeloma (MM), which i …
Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin.
Dalva-Aydemir S, et al. Clin Cancer Res 2015. PMID 25542900 Free PMC article.
RESULTS: Ritonavir-treated multiple myeloma cells exhibited increased reliance on glutamine metabolism. Ritonavir sensitized multiple myeloma cells to metformin, effectively eliciting cytotoxicity both in vitro and in an in vivo xenograft model of multiple myeloma and in breast, ovarian, and melanoma cancer cell lines. ...CONCLUSIONS: FDA-approved ritonavir and metformin effectively target multiple myeloma cell metabolism to elicit cytotoxicity in multiple myeloma. ...
RESULTS: Ritonavir-treated multiple myeloma cells exhibited increased reliance on glutamine metabolism. Ritonavir sensi …
Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options.
van Andel H, et al. Leukemia 2019 - Review. PMID 30770859 Free PMC article.
In multiple myelomas (MMs), however, these pathway intrinsic mutations are rare despite the fact that most tumors display aberrant Wnt pathway activity. ...
In multiple myelomas (MMs), however, these pathway intrinsic mutations are rare despite the fact that most tumors display aberrant Wn …
Hypoxia-inducible KDM3A addiction in multiple myeloma.
Ikeda S, et al. Blood Adv 2018. PMID 29444873 Free PMC article.
In multiple myeloma (MM), the bone marrow (BM) microenvironment may contain a myeloma cell fraction that has acquired treatment resistance by undergoing an epigenetic gene expression change. ...Thus, this axis is a promising therapeutic target against myeloma cells in the BM microenvironment....
In multiple myeloma (MM), the bone marrow (BM) microenvironment may contain a myeloma cell fraction that has acquired t …
Extracellular Vesicles Enhance Multiple Myeloma Metastatic Dissemination.
Colombo M, et al. Int J Mol Sci 2019 - Review. PMID 31266187 Free PMC article.
Multiple myeloma (MM) is a hematological neoplasm that mostly relies on the bone marrow (BM). The BM represents a highly supportive niche for myeloma establishment and diffusion during the formation of distant bone lesions typical of this disease. This review represents a survey of the most recent evidence published on the role played by EVs in supporting MM cells during the multiple steps of metastasis, including travel and uptake at distant premetastatic niches, MM cell engraftment as micrometastasis, and expansion to macrometastasis thanks to EV-induced angiogenesis, release of angiocrine factors, activation of osteolytic activity, and mesenchymal cell support. ...
Multiple myeloma (MM) is a hematological neoplasm that mostly relies on the bone marrow (BM). The BM represents a highly suppo
Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma.
Lê GN, et al. Mol Omics 2019 - Review. PMID 30652172
Multiple myeloma, an incurable malignancy of the plasma cells in the bone marrow, has a complex pathogenesis due to clonal heterogeneity. Over the years, many clinical trials and researches have led to the development of effective myeloma treatments, resulting in survival prolongation. ...
Multiple myeloma, an incurable malignancy of the plasma cells in the bone marrow, has a complex pathogenesis due to clonal het
Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells.
An N, et al. Mol Pharm 2018. PMID 30185037
The CD38-CAR-Ts effectively lysed CD38(+) MM cell lines, including LP-1, RPMI 8226, OPM2, and MOLP8, and primary MM cells from multiple myeloma patients. ...These results demonstrate that the CD38-CAR-Ts constructed with the anti-CD38 nanobody are a promising approach for the treatment of multiple myeloma....
The CD38-CAR-Ts effectively lysed CD38(+) MM cell lines, including LP-1, RPMI 8226, OPM2, and MOLP8, and primary MM cells from multiple
KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival.
Ohguchi H, et al. Leukemia 2017. PMID 28487543 Free PMC article.
Here we show that KDM6B is expressed in multiple myeloma (MM) cells; and that shRNA-mediated knockdown and CRISPR-mediated knockout of KDM6B abrogate MM cell growth and survival. ...
Here we show that KDM6B is expressed in multiple myeloma (MM) cells; and that shRNA-mediated knockdown and CRISPR-mediated kno …
Role of Galectins in Multiple Myeloma.
Storti P, et al. Int J Mol Sci 2017 - Review. PMID 29258207 Free PMC article.
Multiple myeloma (MM) is a plasma cell (PC) malignancy characterized by the tight adhesion between tumoral PCs and bone marrow (BM) microenvironment, leading to the increase of PC survival and drug resistance, MM-induced neo-angiogenesis, immunosuppression and osteolytic bone lesions. ...
Multiple myeloma (MM) is a plasma cell (PC) malignancy characterized by the tight adhesion between tumoral PCs and bone marrow
4,112 results
Jump to page
Feedback